Premnath V | Drugs Monitor

(27 Oct 2020) Dexamethasone- associated with decreased mortality among those requiring respiratory support

October 31, 2020

Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study https://www.medrxiv.org/content/10.1101/2020.10.23.20218172v1 Among patients who required respiratory support, the end-point event of death occurred in 10 patients (15.9%) who received dexamethasone and 298 patients (26.4%)… Continue reading "(27 Oct 2020) Dexamethasone- associated with decreased mortality among those requiring respiratory support"

(27 Oct 2020) Ivermectin- combination with Doxycycline shows higher success rate when administered early

October 31, 2020

Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1 Randomized controlled study (NCT04591600) on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per… Continue reading "(27 Oct 2020) Ivermectin- combination with Doxycycline shows higher success rate when administered early"

(27 Oct 2020) Itolizumab- in combination with other antivirals reduces COVID-19 disease worsening and mortality

October 31, 2020

Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19 https://doi.org/10.1159/000512210 19 patients were included in an expanded access clinical trial to receive itolizumab, an anti-CD6 monoclonal antibody in Cuba. All patients had underlying medical conditions.… Continue reading "(27 Oct 2020) Itolizumab- in combination with other antivirals reduces COVID-19 disease worsening and mortality"

(25 Oct 2020) Arbidol- showed beneficial effects on fever recovery, viral clearance and shorter hospital stay in males

October 31, 2020

Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series https://doi.org/10.1186/s12985-020-01428-5 In the retrospective COVID-19 cohort, gender was one of the important factors affecting patient’s conditions. Arbidol… Continue reading "(25 Oct 2020) Arbidol- showed beneficial effects on fever recovery, viral clearance and shorter hospital stay in males"

(21 Oct 2020) Tocilizumab- not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19

October 22, 2020

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2028836 A randomized, double-blind, placebo-controlled trial ( NCT04356937) involving patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two of the following signs: fever (body temperature… Continue reading "(21 Oct 2020) Tocilizumab- not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19"

(21 Oct 2020) Hydroxychloroquine- older patients with mild-to-moderate COVID-19 did not experience better clinical or virological outcomes

October 22, 2020

A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19 https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1 A multicentre randomized double-blind placebo-controlled trial ( NCT04325893) evaluating hydroxychloroquine in older COVID-19 patients was conducted . Eligible patients were randomized in a 1:1 ratio to receive either 800 mg… Continue reading "(21 Oct 2020) Hydroxychloroquine- older patients with mild-to-moderate COVID-19 did not experience better clinical or virological outcomes"

(20 Oct 2020) Methylprednisolone- significantly lower hazard of death (71%) and decreased ventilator dependence

October 22, 2020

Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia https://doi.org/10.1093/ofid/ofaa421 We conducted a multicenter observational study (NCT04323592) to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite… Continue reading "(20 Oct 2020) Methylprednisolone- significantly lower hazard of death (71%) and decreased ventilator dependence"

(18 Oct 2020) Hydroxychloroquine- No significant reduction in incidence of COVID 19 among health workers

October 22, 2020

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1571/5929230 A randomized, double-blind, placebo-controlled clinical trial (NCT04328467) of healthcare workers with ongoing exposure to persons with SARS-CoV-2 was conducted. Participants across the United States and in the… Continue reading "(18 Oct 2020) Hydroxychloroquine- No significant reduction in incidence of COVID 19 among health workers"

(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19

October 17, 2020

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 The interim results from Solidarity trials (ISRCTN83971151 , NCT04315948 ) are presented. In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon… Continue reading "(15 Oct 2020) Remdesivir, Hydroxychloroquine, Lopinavir and Interferon- Interim results from Solidarity trial suggests these have little or no effect on hospitalized COVID-19"

(14 Oct 2020) Lopinavir/R- high rate of adverse events (10/23, 43%)

October 17, 2020

Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19 https://pubmed.ncbi.nlm.nih.gov/33048786/ An observational, retrospective, single-center study involving adult patients with severe SARS-CoV-2 infection was conducted. All adverse events detected in 23 patients in the Intensive Care Unit between March 15… Continue reading "(14 Oct 2020) Lopinavir/R- high rate of adverse events (10/23, 43%)"

Author: Premnath V